VBIV (VBI Vaccines, Inc.) מחיר חזוי לרווח

VBI Vaccines Inc. minimizes operational risks through an extensive network of external research centers. The brand's scientific authority is confirmed by the development of an innovative hepatitis B vaccine. The company's estimated forward P/E on GURU.Markets captures valuation dynamics, where 0.00 serves as the current metric level. The business's financial stability is based on government contracts and commercial drug sales.
פילוחים אנליטיים של חברת VBI Vaccines Inc.

For the biotech business of VBI Vaccines Inc. (VBIV) with high R&D expenditures, the company's forward P/E ratio serves as an indicator of market expectations for future earnings. The ratio of the current share price to the projected EPS allows for an assessment of the discount or premium, accounting for the high operating leverage that is activated during the transition from vaccine development to mass low-cost production.